Hyeong-Moo Shin1, Deborah H Bennett2, Antonia M Calafat3, Daniel Tancredi4, Irva Hertz-Picciotto5. 1. Department of Earth and Environmental Sciences, University of Texas, Arlington, TX, USA. Electronic address: hyeongmoo.shin@uta.edu. 2. Department of Public Health Sciences, University of California, Davis, CA, USA. 3. Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Department of Pediatrics, University of California, Davis, CA, USA. 5. Department of Public Health Sciences, University of California, Davis, CA, USA; UC Davis MIND (Medical Investigations of Neurodevelopmental Disorders) Institute, Sacramento, CA, USA.
Abstract
BACKGROUND/ OBJECTIVE: Per- and polyfluoroalkyl substances (PFAS) display neurobehavioral toxicity in laboratory animal studies. We examined associations of modeled prenatal maternal exposure to PFAS with child diagnosis of autism spectrum disorder (ASD). METHODS: Participants were 453 mother-child pairs from CHARGE (CHildhood Autism Risk from Genetics and Environment), a population-based case-control study. Children underwent psychometric testing and were clinically confirmed for ASD (n = 239) or typical development (TD, n = 214). At the end of the clinic visit, maternal blood specimens were collected. We quantified nine PFAS in maternal serum samples collected when their child was 2-5 years old. As surrogate in utero exposure, we used a model built from external prospective data in pregnancy and 24 months post-partum and then reconstructed maternal PFAS serum concentrations during pregnancy in this case-control sample. We used logistic regression to evaluate associations of modeled prenatal maternal PFAS concentrations with child ASD. RESULTS: Modeled prenatal maternal perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) were borderline associated with increased odds of child diagnosis of ASD (per nanogram per milliliter increase: odds ratio [OR] = 1.46; 95% confidence interval [CI]: 0.98, 2.18 for PFHxS, OR = 1.03; 95% CI: 0.99, 1.08 for PFOS). When compared to the lowest quartile (reference category), the highest quartile of modeled prenatal maternal PFHxS was associated with increased odds of child diagnosis of ASD (OR = 1.95; 95% CI: 1.02, 3.72). CONCLUSIONS: In analyses where modeled prenatal maternal PFAS serum concentrations served as in utero exposure, we observed that prenatal PFHxS and PFOS exposure, but not other PFAS, were borderline associated with increased odds of child diagnosis of ASD. Further studies in which PFAS concentrations are prospectively measured in mothers and children at a range of developmental stages are needed to confirm these findings.
BACKGROUND/ OBJECTIVE:Per- and polyfluoroalkyl substances (PFAS) display neurobehavioral toxicity in laboratory animal studies. We examined associations of modeled prenatal maternal exposure to PFAS with child diagnosis of autism spectrum disorder (ASD). METHODS:Participants were 453 mother-child pairs from CHARGE (CHildhood Autism Risk from Genetics and Environment), a population-based case-control study. Children underwent psychometric testing and were clinically confirmed for ASD (n = 239) or typical development (TD, n = 214). At the end of the clinic visit, maternal blood specimens were collected. We quantified nine PFAS in maternal serum samples collected when their child was 2-5 years old. As surrogate in utero exposure, we used a model built from external prospective data in pregnancy and 24 months post-partum and then reconstructed maternal PFAS serum concentrations during pregnancy in this case-control sample. We used logistic regression to evaluate associations of modeled prenatal maternal PFAS concentrations with childASD. RESULTS: Modeled prenatal maternal perfluorohexane sulfonate (PFHxS) and perfluorooctane sulfonate (PFOS) were borderline associated with increased odds of child diagnosis of ASD (per nanogram per milliliter increase: odds ratio [OR] = 1.46; 95% confidence interval [CI]: 0.98, 2.18 for PFHxS, OR = 1.03; 95% CI: 0.99, 1.08 for PFOS). When compared to the lowest quartile (reference category), the highest quartile of modeled prenatal maternal PFHxS was associated with increased odds of child diagnosis of ASD (OR = 1.95; 95% CI: 1.02, 3.72). CONCLUSIONS: In analyses where modeled prenatal maternal PFAS serum concentrations served as in utero exposure, we observed that prenatal PFHxS and PFOS exposure, but not other PFAS, were borderline associated with increased odds of child diagnosis of ASD. Further studies in which PFAS concentrations are prospectively measured in mothers and children at a range of developmental stages are needed to confirm these findings.
Authors: Laurel A Schaider; Ruthann A Rudel; Janet M Ackerman; Sarah C Dunagan; Julia Green Brody Journal: Sci Total Environ Date: 2013-09-17 Impact factor: 7.963
Authors: Henry M Spliethoff; Lin Tao; Shannon M Shaver; Kenneth M Aldous; Kenneth A Pass; Kurunthachalam Kannan; George A Eadon Journal: Environ Sci Technol Date: 2008-07-15 Impact factor: 9.028
Authors: Xiangmei May Wu; Deborah H Bennett; Antonia M Calafat; Kayoko Kato; Mark Strynar; Erik Andersen; Rebecca E Moran; Daniel J Tancredi; Nicolle S Tulve; Irva Hertz-Picciotto Journal: Environ Res Date: 2014-11-20 Impact factor: 6.498
Authors: Irva Hertz-Picciotto; Ake Bergman; Britta Fängström; Melissa Rose; Paula Krakowiak; Isaac Pessah; Robin Hansen; Deborah H Bennett Journal: Environ Health Date: 2011-01-05 Impact factor: 5.984
Authors: Kristen Lyall; Vincent M Yau; Robin Hansen; Martin Kharrazi; Cathleen K Yoshida; Antonia M Calafat; Gayle Windham; Lisa A Croen Journal: Environ Health Perspect Date: 2018-01-02 Impact factor: 9.031
Authors: Megan Bragg; Jorge E Chavarro; Ghassan B Hamra; Jaime E Hart; Loni Philip Tabb; Marc G Weisskopf; Heather E Volk; Kristen Lyall Journal: Curr Environ Health Rep Date: 2022-03-19
Authors: Jiwon Oh; Deborah H Bennett; Antonia M Calafat; Daniel Tancredi; Dorcas L Roa; Rebecca J Schmidt; Irva Hertz-Picciotto; Hyeong-Moo Shin Journal: Environ Int Date: 2020-12-30 Impact factor: 13.352